Chi-square tests were performed to study the relationships between CD8+ T cell, CD8+PD-L1+ T cell, or CD68+CD163+ M2 macrophage infiltration and the response rate of NSCLC patients who received ICI therapy. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.